TERMINATIONS OF PREGNANCY FOR EXPOSURE TO ORAL RETINOIDS IN SOUTH-AUSTRALIA, 1985-1993

被引:14
作者
CHAN, A
KEANE, RJ
HANNA, M
ABBOTT, M
机构
[1] South Australian Health Commission, Bedford Park
[2] Flinders Medical Centre, Bedford Park, South Australia
关键词
D O I
10.1111/j.1479-828X.1995.tb02157.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The oral retinoids, isotretinoin and etretinate, are highly teratogenic drugs which have been available in Australia since 1985 because of their unique effectiveness in severe cystic acne, psoriasis and other keratinization disorders. Only dermatologists can prescribe them, but in spite of strict guidelines by the manufacturers and the College of Dermatologists, exposed pregnancies have occurred. We attempted to determine the circumstances of exposure to these drugs for the 18 pregnancies terminated in South Australia in 1985-1993, using questionnaires to medical practitioners who notified the terminations under legislation. The main reason for their occurrence was the lack of compliance with the use of effective contraception by the women. In South Australia, some prescriptions of oral retinoids by unauthorized doctors have been dispensed during this period. Using statistics on prescriptions dispensed, an estimate was made of 1 termination of pregnancy for 319 courses of treatment for women with isotretinoin. Extension of guidelines for prescription and more detailed counselling in relation to the use of contraception are recommended, It is also suggested that doctors intending to recommend terminations obtain consent to discuss exposure with the dermatologists concerned, who may not be aware of the exposed pregnancy.
引用
收藏
页码:422 / 426
页数:5
相关论文
共 16 条
[1]  
Rosa FW, Wilk AL, Kelsey FO., Teratogen Update: Vitamin A Congeners, Teratology, 33, pp. 355-364, (1986)
[2]  
Rosa FW., Teratogenicity of isotretinoin, (Letter) Lancet, 2, (1983)
[3]  
Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Et al., N, Engl J Med, 313, pp. 837-841, (1985)
[4]  
Ayme S, Julian C, Gambarelli D, Marotti B, Maurin N., Isotretinoin dose and teratogenicity. (Letter), Lancet, 1, (1988)
[5]  
Dai WS, LaBraico JM, Stem RS., Epidemiology of isotretinoin exposure during pregnancy, J Am Acad Dermatol, 26, pp. 599-606, (1992)
[6]  
Bigby M, Stem RS, Adverse reactions to isotretinoin, J Am Acad Dermatol, 18, pp. 543-552, (1988)
[7]  
Hogan DJ, Strand LM, Lane PR., Isotretinoin therapy for acne: a population based study, Can Med Assoc J, 138, pp. 47-50, (1988)
[8]  
Lancaster PAL, Rogers JG., Isotretinoin use in pregnancy (Letter), Med J Aust, 148, pp. 654-655, (1988)
[9]  
Annual Reports for the years 1985–1993
[10]  
Lee M, Cooper A., Survey of Australian Isotretinoin Prescribing, Australas J Dermatol, 32, pp. 13-16, (1991)